Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
SALT LAKE CITY, TORONTO & MONTRÉAL (May 8, 2023) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence. “Recursion has pioneered the massive, parallel generation of -omics data with […]
Cyclica to help expand Canadian platform for federated AI-powered insights in genomics and precision health
Toronto, Ontario — Today, a Canadian consortium, including Cyclica inc., (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, is announcing the launch of a new project to expand the development of a software platform to enable federated, AI-powered insights across networks of genomics and health data. The Canadian Platform […]
Cyclica teams up with Uruguay national research agency, ANII, to enhance scientific innovation
09 March 2023, Toronto, Canada and Montevideo, Uruguay – Cyclica Inc. (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and the National Research and Innovation Agency (“Agencia Nacional de Investigación e Innovación” or ANII”), a Uruguayan government agency that funds and promotes research and innovation initiatives, announce a […]
Cyclica’s 2022 Year in Review
Cyclica and SK Chemicals announce agreement to co-develop novel therapeutics
Toronto, Canada and Seongnam-si, South Korea – Cyclica Inc. (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and SK Chemicals Co., Ltd. (“SK Chemicals”), a global leader in total healthcare providing diagnostic, therapeutic and prophylactic solutions, today announced an AI-driven drug discovery and development partnership to develop therapies […]
Naheed Kurji appointed to OBIO Board of Directors
TORONTO, December 1, 2022 – OBIO®, a not-for-profit organization dedicated to advancing health technology innovation and commercialization, is pleased to announce the appointment of a new chair of its board of directors, Frank Florio, as well as the addition of three new members, Dr. Wendy Naimark, Naheed Kurji and Anne Woods. Mr. Florio, an accomplished […]
Cyclica receives CAD$2.4M grant for a multi-targeted drug discovery program to advance non-hormonal contraceptive medicines
Cyclica receives a grant from the Bill & Melinda Gates Foundation to apply its AI-enabled drug discovery platform to discover new therapeutic options for multiple low-data biological targets with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries. TORONTO, CANADA — November 15, 2022: Cyclica Inc., a neo-biotech […]
[White paper] Exploring the unexplored, drugging the undrugged: How Cyclica is opening new frontiers in drug discovery
Co-Development Agreement using AI Drug Discovery between Samjin Pharm. and Cyclica
Seoul, South Korea and Toronto, Canada – Samjin Pharmaceuticals Co., Ltd. (“Samjin”; CEO, Yong Ju Choi) a pharmaceutical company devoted to develop innovative drugs to treat diseases with high unmet medical needs, and Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance arobust and sustainable drug discovery pipeline announced today a co-development agreement for […]
Cyclica and Oncocross announce partnership to develop therapeutics in oncology
Toronto, Canada and Seoul, Korea – Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Oncocross Co., Ltd. (“Oncocross”), a biotech revolutionizing the drug development process through its unique AI approach based on transcriptome database, announce a drug discovery partnership to advance the development of […]